<DOC>
	<DOCNO>NCT00891007</DOCNO>
	<brief_summary>Partially randomize , control Phase II study evaluate safety , immunogenicity dose response measles vaccine MVA mBN85B healthy child age 6 month 6 year .</brief_summary>
	<brief_title>Study Evaluate Safety , Dose Response Immunogenicity Measles Vaccine MVA mBN85B Healthy Children Aged 6 Months 6 Years</brief_title>
	<detailed_description>Open label study assess safety immunogenicity MVA-mBN85B healthy vaccine-naive , measles-naive measles-experienced child . The study comprise three group 30 child . Two group receive two subcutaneous ( s.c. ) immunization 4 week ( 28±3 day ) apart either either 1 x 10E7 TCID50 ( Group A ) 1 x 10E8 TCID50 ( Group B ) MVA mBN85B . The control group ( Group C ) receive two s.c. dos ( 0.5 ml , 1000 TCID50 ) Rouvax® ( Sanofi-Pasteur ) 24 week apart .</detailed_description>
	<mesh_term>Measles</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Read , sign date informed consent document one parent/guardian child advise risk benefit study language understood parent/guardian . This document must sign prior performance study specific procedure . 2 . Male female child age 6 month 6 year ( Group C : 9 month 6 year ) . 3 . Prior prior measles vaccination indicate RTHC . 4 . No known exposure measles within 30 day prior study entry . 5 . No history measles disease . 6 . Negative human immunodeficiency virus antibody test ( antiHIV ) hepatitis B surface antigen ( HBsAG ) . 7 . Child good health determine medical history , physical examination clinical judgment . 8 . Children investigator reasonably believe parents/guardian comply requirement protocol 1 . Any clinically significant condition may influence participation study , include febrile convulsion . 2 . Severe malnutrition assess investigator weight age clinical criterion . 3 . History splenectomy . 4 . Clinically significant anaemia ( laboratory clinical criterion ) . 5 . Having receive vaccination plan vaccination live vaccine within 30 day prior study vaccination . 6 . Having receive vaccination plan vaccination kill vaccine within 14 day prior study vaccination . 7 . Administration plan administration immunoglobulin and/or blood product period start 3 month prior administration vaccine end study conclusion . 8 . Use investigational nonregistered drug vaccine study vaccine within 30 day precede first dose study vaccine , plan administration drug study period . 9 . History serious medical condition , opinion investigator , would compromise safety child . 10 . History currently active autoimmune disease . Children vitiligo thyroid disease thyroid replacement therapy exclude . 11 . History malignancy , especially leukaemia lymphoma . 12 . History allergic disease reaction likely exacerbate component vaccine . 13 . History anaphylaxis severe allergic reaction . 14 . Known allergy egg protein , gelatine , neomycin gentamycin . 15 . Chronic administration ( defined 14 day ) systemic high dose immunosuppressant drug period start six month prior administration vaccine end study conclusion . High dose define 2 mg/kg/day prednisolone equivalent , 20 mg/day child weigh 10 kg . 16 . Previous participation MVAbased vaccination study</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Measles</keyword>
	<keyword>Virus Disease</keyword>
	<keyword>Paediatric Diseases</keyword>
	<keyword>Paramyoxyviridae</keyword>
</DOC>